AUM Biosciences Ltd CEO Vishal Doshi sits down with Proactive’s Elisha Newell to discuss the company’s vision heading into 2023. In a nutshell, AUM is out to combat a wide range of cancers (especially those with high unmet medical need) with a varied portfolio of precision therapeutics. The company is working with a special purpose acquisition company (SPAC) to pursue a Nasdaq listing, and Doshi says there’s plenty more news to come in 2023.
AUM Biosciences has big plans for oncology pipeline in 2023
